Results 11 to 20 of about 135,285 (241)
Computational and Structural Biotechnology Journal, 2020 There are no approved target therapeutics against SARS-CoV-2 or other beta-CoVs. The beta-CoV Spike protein is a promising target considering the critical role in viral infection and pathogenesis and its surface exposed features. We performed a structure-
João Trigueiro-Louro +4 more
doaj +1 more source
Antiviral drugs and antiviral drug resistance [PDF]
Current Opinion in Virology, 2011 Antiviral drugs and antiviral drug resistance can be matters of life and death for patients suffering from viral infections. They also can be valuable tools for understanding virus biology and biochemistry. Triumphs of antiviral therapy include acyclovir to treat genital herpes [1–4], triple combination chemotherapy for AIDS [5,6], and, quite recently,
Donald M, Coen, Richard J, Whitley
openaire +2 more sources
BMJ, 1998 The development of effective antiviral drugs is an important biomedical scientific achievement of the late 20th century. Highly potent drugs are now available against herpes viruses, HIV, hepatitis B virus, and influenza virus. This list will extend to papillomaviruses, respiratory viruses, enteroviruses, and hepatitis C virus over the next 5-10 years.
D, Pillay, M, Zambon
openaire +4 more sources
Retrovirology, 2017 The first responders of human antiviral immunity are components of the intrinsic immune response that reside within each and every one of our cells.
Guoli Shi +2 more
doaj +1 more source
Frontiers in Microbiology, 2020 Hepatitis B virus (HBV) is a highly variable DNA virus due to its unique life cycle, which involves an error-prone reverse transcriptase. The high substitution rate drives the evolution of HBV by generating genetic variants upon which selection operates.
Natalia M. Araujo +2 more
doaj +1 more source
Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade [PDF]
Clinical and Molecular Hepatology, 2013 Although much advancement has been achieved in the treatment of chronic hepatitis B, antiviral resistance is still a challenging issue. Previous generation antiviral agents have already developed resistance in a number of patients, and it is still being ...
Hyung Joon Yim, Seong Gyu Hwang
doaj +1 more source
New Treatment Options for Refractory/Resistant CMV Infection
Transplant International, 2023 Despite advances in monitoring and treatment, cytomegalovirus (CMV) infections remain one of the most common complications after solid organ transplantation (SOT).
Carla Simone Walti +3 more
doaj +1 more source
Molecular Basis of Encapsidation of Hepatitis C Virus Genome
Frontiers in Microbiology, 2018 Hepatitis C virus (HCV), a major etiologic agent of human liver diseases, is a positive-sense single-stranded RNA virus and is classified in the Flaviviridae family.
Guoli Shi, Tetsuro Suzuki
doaj +1 more source
Viruses, 2023 Nirmatrelvir, which targets the SARS-CoV-2 main protease (Mpro), is the first-in-line drug for prevention and treatment of severe COVID-19, and additional Mpro inhibitors are in development.
Karen Anbro Gammeltoft +11 more
doaj +1 more source
Suppression of CMV Infection with Letermovir in a Kidney Transplant Patient
European Journal of Case Reports in Internal Medicine, 2020 Infection with cytomegalovirus (CMV) with resistance to ganciclovir (GCV) is a therapeutic challenge in kidney transplant patients, because standard treatment options are nephrotoxic. We report the case of a kidney transplant recipient with GCV-resistant
Uta Köpf +6 more
doaj +1 more source